Paradoxically, fatigue is among the commonly reported adverse effects of GLP-1 therapy, particularly during the initial weeks of treatment or following dose escalation
WADA and Athletic Bans MOTSc falls under WADAs Prohibited List , category S2 Classified alongside peptide hormones, growth factors, and related substances Banned in- and out-of-competition Positive tests may result in disqualification or suspension WADA prohibits all synthetic analogues of mitochondrial and peptide growth factors, including MOTS-c. World Anti-Doping Agency, Prohibited List Global Legal Overview Canada, UK, Australia : MOTSc is legal for research but not human use EU : Generally treated the same as RUO peptides
The oral presentation, titled, Pancreatic Gene Therapy Durably Improves Glycemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes, highlighted the promising implications of the Rejuva platform in potentially reshaping the treatment landscape for T2D and obesity with a GLP-1 based pancreatic gene therapy candidate (GLP-1 PGTx) designed to target the pancreas to provide long-term metabolic benefits from a single administration
After 20 weeks of treatment, the study randomly assigned patients to keep taking the drug or to discontinue it
The SUSTAIN 6 trial specifically demonstrated cardiovascular benefits in this high-risk group
No, stopping suddenly can cause withdrawal
&srotate=0)
